RedHill’s Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
The study was done in collaboration with renowned virologist, Dr. Colleen B. Jonsson, Harriet Van Vleet Professor of Virology, Director of the Regional Biocontainment Laboratory (RBL), and Director of the Institute for the Study of Host-Pathogen Systems at the University of Tennessee Health Sciences Center (UTHSC), who remarked: “We tested RHB-107 and opaganib using a primary human nasal epithelial cell… Read More